This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
phttp://www.wikidata.org/prop/
wikibasehttp://wikiba.se/ontology#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1111/
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q92837515
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu n'abril de 2019 наукова стаття, опублікована 3 квітня 2019 im April 2019 veröffentlichter wissenschaftlicher Artikel scientific article published on 03 April 2019 wetenschappelijk artikel
p:P577
wds:Q92837515-F844B3C6-FBBF-468E-9740-B79CB6221CE8
wdt:P577
2019-04-03T00:00:00Z
p:P2093
wds:Q92837515-11FE52D9-42EE-4515-85A6-3CD39E2B88DE
wdt:P2093
Tianjian Zhou
rdfs:label
Discussion of "A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III" by Andrew G. Chapple and Peter F. Thall Discussion of "A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III" by Andrew G. Chapple and Peter F. Thall
skos:prefLabel
Discussion of "A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III" by Andrew G. Chapple and Peter F. Thall Discussion of "A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III" by Andrew G. Chapple and Peter F. Thall
schema:name
Discussion of "A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III" by Andrew G. Chapple and Peter F. Thall Discussion of "A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III" by Andrew G. Chapple and Peter F. Thall
p:P50
wds:Q92837515-49795FFA-E1B9-4A47-8D9F-E3149E819308
wdt:P50
wd:Q91287935
p:P1476
wds:Q92837515-CB3C4A3E-2238-4CC7-9FCE-FF32F98A4071
wdt:P1476
Discussion of "A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III" by Andrew G. Chapple and Peter F. Thall
p:P304
wds:Q92837515-067302A2-AD67-4D1F-8D24-D57B02C736A7
wdt:P304
385-388
p:P31
wds:Q92837515-6A86D86A-D83D-4539-98D2-444C18B5C154
wdt:P31
wd:Q13442814
p:P921
wds:Q92837515-1CFAE519-3CD8-4D93-B2D5-210E2F5A77DF wds:Q92837515-B8A97F04-51CB-47D2-9A93-71CD5CF5E7BE
wdt:P921
wd:Q42824827 wd:Q5452194
p:P698
wds:Q92837515-9D148C6C-17D7-4296-BAFF-7932AA5A7D7C
wdtn:P698
n10:30945260
wdt:P698
30945260
p:P1433
wds:Q92837515-7EBC0368-53BE-4ECB-A8FA-B0BE142A26E4
wdt:P1433
wd:Q2025724
p:P433
wds:Q92837515-F166128E-5353-455D-B143-A199E1E1857B
p:P478
wds:Q92837515-EBF15638-DC38-4E1C-8137-AA93D0908731
wdt:P433
2
wdt:P478
75
p:P356
wds:Q92837515-A2FFB48A-B819-43CE-BD30-467D2578FD4F
wdtn:P356
n12:BIOM.12992
wdt:P356
10.1111/BIOM.12992
p:P6104
wds:Q92837515-7DCACE7D-F960-481D-B5B7-3A80D7453B11
wdt:P6104
wd:Q8487137
p:P894
wds:Q92837515-EBAA5D4D-7FE3-4C05-9891-1764605F3BDF
wdt:P894
1436.62669